A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, phase Ib/II study of APG-2575 as a single agent in
patients with advanced solid tumors or in combination with anti-cancer agents such as CDK 4/6
inhibitor palbociclib in patients with ER+/HER2- metastatic breast cancer (mBC) who have
progressed or relapsed after first line therapy